Clinical Trials for Parkinson's Disease

Source: ClinicalTrials.gov — U.S. National Library of Medicine — A database of privately and publicly funded clinical studies conducted around the world (U.S. National Library of Medicine, public domain).

This page lists clinical trials related to Parkinson’s Disease from the ClinicalTrials.gov database.

Trial Summary

• Total studies: 50
• Recruiting: 25
• Active, not recruiting: 9
• Completed: 9
• Other: 7

Results are refreshed periodically and may not reflect the most current information available from ClinicalTrials.gov.

Recruiting Trials

NCT01581580 — Deep Brain Stimulation Surgery for Movement Disorders

Background:

- Deep brain stimulation (DBS) is an approved surgery for certain movement disorders, like Parkinson’s disease, that do not respond well to other treatments. DBS uses a battery-powered device called a neurostimulator (like a pacemaker) that is placed under the skin in the chest. It is used to stimulate the areas of the brain that affect movement. Stimulating these areas helps to b…

NCT01682668 — Subthalamic Nucleus, Akinesia and Parkinson’s Disease

This program aims to understand the role of the subthalamic nucleus in the control of the movement in healthy humans and patients with Parkinson’s disease, how the STN dysfunction contributes to akinesia and how the STN stimulation improves motor signs in PD patients .

NCT02071134 — Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific’s commercially available Vercise DBS System in the treatment of Parkinson’s disease.

The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific’s Vercise DB…

NCT05901818 — Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson’s Disease

This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson’s Disease patients.

NCT04396873 — PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

Background:

About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation.

Objective:

To learn whether COX-1 and/or COX-2 is elevated in the brains of individuals with neurodegenerative brain …

NCT07679256 — Integrated Digital and Neurogenic Exosome Biomarkers for Early Diagnosis of Parkinson’s Disease: Development and Application

Based on the high-quality Parkinson’s disease cohort population and biological sample database in the early stage of the team, multi-dimensional intelligent wearable device technology and machine learning were used to screen and classify digital biomarkers in the prodromal PD cohort, early PD cohort and healthy population cohort. Using peptide nanoprobes, metabolomics and Simoa technology to fi…

NCT06464029 — Pathways Mediating Impaired Postural Control in Parkinson’s Disease

The purpose of this project is to use transcranial magnetic stimulation (TMS) to explore the state of excitability of corticocortical and corticofugal (cortex to spinal cord, cortex to brainstem to spinal cord) pathways that project to muscles that control the legs and trunk in people with Parkinson’s disease. The outcome variables will be further analyzed to understand their relationship to qu…

NCT06680830 — A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson’s Disease

The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson’s Disease (PD) who have predicted elevations in the activity of the “leucine-rich repeat kinase 2” (“LRRK2” for short) pathway based on their genetic profile. A DNA test will be used to identify the “LRRK2-driven” population with predicted elevation…

NCT07094269 — Protocol of the Packer Managing Fatigue Program Versus Standard Information to Improve Energy Conservation Self-Efficacy in Parkinson’s Disease

This protocol describes a randomized, controlled, parallel-group, trial evaluating the effectiveness of a group-based fatigue management program for people with Parkinson’s disease. The study will be conducted in Italy, with participant recruitment planned to begin on July 1st, 2025. The primary sponsor is the Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal Chil…

NCT06920134 — Epidural Electrical Stimulation to Support Hemodynamic Management in Individuals With Parkinson’s Disease

The PD-HemON study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support hemodynamic management in people with typical and atypical Parkinson’s Disease, who suffer from orthostatic hypotension.

NCT07680725 — The Effect of Bottle PEP Exercise on Expiratory Muscle Thickness, Strength, and Balance Parameters in Parkinson’s Disease Patients

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by rigidity, tremor, postural instability, bradykinesia, and autonomic dysfunction. It is a common movement disorder worldwide. Motor impairments in PD patients are not limited to the muscles of the extremities; the neck, upper respiratory tract, and respiratory muscles are also affected. The resulting pulmonary …

NCT07115563 — Daily Amino Acid Supplementation for People With Parkinson’s Disease

The goal of this clinical trial is to learn if a tailored amino acid supplement works to help adults living with Parkinson’s disease to improve nutrition, metabolic function, body composition, and physical and mental function. The main questions it aims to answer are:

Does the tailored amino acid supplement increase essential amino acids (nutritional status)?

Does the tailored amino acid supp…

NCT07284342 — A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson’s Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa

Parkinson’s disease (PD) is a neurological condition, which affects the brain. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess change in sleep disturbances of adult participants with advanced Parkinson’s disease receiving subcutaneous Foslevodopa/Foscarbidopa under routine clinical practice.

Foslevodopa/Foscarbidopa is an approved drug for the treat…

NCT07174310 — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson’s Disease

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson’s disease (PD) on stable symptomatic monotherapy with levodopa.

NCT06857851 — Optimizing Deep Brain Stimulation to Improve Visuomotor Function in Parkinson’s Disease

Inability to align and refocus the eyes on the objects at different depths, i.e., vergence impairment and strabismus, frequently affects the quality of life in patients with Parkinson’s disease. The investigators study aims to understand the location-specific effects of subthalamic region deep brain stimulation on vergence and strabismus by integrating the patient-specific deep brain stimulatio…

NCT07428447 — Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson’s Disease

Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson’s disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have pro…

NCT07687979 — Mobile Application for Gait Training in Parkinson’s Disease

The developed mobile application provides patient-specific metronome-based auditory cues and simultaneous tactile vibrations to regulate walking rhythm. In this study, the effects of the mobile application on walking performance and balance in patients with Parkinson’s disease will be examined in a single-center, controlled design. Participants will undergo gait training for 30 minutes per day,…

NCT07682532 — L-THEANINE AND MEDITERRANEAN DIET ON RBD, GI FUNCTION, AND INFLAMMATION IN PARKINSON’S DISEASE

Parkinson’s disease is a progressive neurological disorder associated with severe dopaminergic neuron loss in the substantia nigra pars compacta. The decrease in dopamine cells in the gut in Parkinson’s disease negatively affects bowel movements, and constipation is a common condition. Impairment of the intestinal barrier increases inflammation. Reactive oxygen species increase, and intestinal …

NCT07213219 — PET-MRI of Reward System in Parkinson’s Disease With RBD

Impulse control disorders (ICDs) are frequently observed in Parkinson’s disease (PD) and can have a major functional impact on the quality of life of both the patient and their entourage. The primary risk factor for the emergence of ICDs in PD is long-term dopaminergic treatment, but other risk factors, such as rapid eye movement sleep behavior disorder (RBD), have recently been identified. The…

NCT07629115 — A Long-Term Follow-up Study of the Severe Parkinson’s Disease Patients Administered the IPS101A Gene Therapy Product.

The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.

NCT07682311 — Automated Daytime Adaptive Deep Brain Stimulation Parameter Optimization in Patients Implanted With Percept Neurostimulator

Parkinson’s disease (PD) affects ~1% of people over 60 years old, is highly disabling and represents a large economic burden. While dopaminergic medications effectively treat motor symptoms early in the disease, most patients develop complications, including motor fluctuations and dyskinesias, which can be partially managed by deep brain stimulation (DBS). This surgical therapy consists of del…

NCT07381751 — Artificial Intelligence-assisted MDS-UPDRS Assessment for Parkinson’s Disease

Idiopathic Parkinson’s disease (PD) is a neurodegenerative disease that progressively causes both motor and non-motor symptoms. As the second most common neurodegenerative disease and most common movement disorder, it affects over 8.5 million people worldwide and 13,000 people in Hong Kong. The most classical symptoms of PD are resting tremors, rigidity of the muscles, bradykinesia (slowing of …

NCT07604116 — A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA

The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.

NCT07685873 — Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease

To evaluate the potential usefulness of 18F-FPyCO/SMBT-1 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various MAO-B-related disease patients.

NCT07641556 — The Effects of Tele-Rehabilitation-Based Dual-Task Upper Extremity Training in Patients With Parkinson’s Disease

The aim of this study is to compare the effects of tele-rehabilitation-based synchronous and asynchronous dual-task upper extremity training with clinical based dual-task upper extremity training and conventional single-task upper extremity training in patients with Parkinson’s disease. The main questions it aims to answer are:

• Whether there are differences in motor symptoms, hand dexterity,…

Active, Not Recruiting

NCT02305147 — Cohort Study to Identify Predictor Factors of Onset and Progression of Parkinson’s Disease

Observational, prospective, monocentric study to assess clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients and rate of progression compared to healthy controls (HC) and subjects at risk to develop PD.

The primary objective of this study is to identify clinical, imaging and biologic markers of PD onset and progression for use in clinical trials of disease-modi…

NCT02994719 — Gait Analysis in Neurological Disease

The purpose of this study is to investigate whether speed-dependent measures of gait (so called gait signatures) can be identified in patients with neurological conditions that affect gait, particularly in subjects with parkinsonian disorders.

NCT03648905 — Clinical Laboratory Evaluation of Chronic Autonomic Failure

Background:

The autonomic nervous system controls automatic body functions. Researchers want to improve the tests used to diagnose autonomic failure. Orthostatic hypertension is a drop in blood pressure when a person stands up. Researchers want to focus on this sign of autonomic failure.

Objective:

To improve testing for conditions that cause autonomic nervous system failure.

Eligibility:

…

NCT07681609 — Proprioceptive Exercise in Parkinson’s Disease

Parkinson’s disease is frequently associated with impaired postural control, balance deficits, trunk misalignment, altered proprioception, and an increased risk of falls. These impairments may contribute to reduced mobility, pain, loss of independence, and decreased quality of life. Although rehabilitation is a key component of Parkinson’s disease management, conventional approaches often focus…

NCT05459753 — Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)

To perform a prospective cohort study with [(18)F]fluoroethoxybenzovesamicol (FEOBV) brain PET at baseline and 2-year follow-up in PD subjects at risk of conversion to non-episodic and episodic (falls and FoG) PIGD motor features and cognitive changes at the same time points.

NCT05808504 — Investigation of the Benefits of Electrical Non-invasive Stimulation on Cognitive Symptoms in Parkinson’s Disease

Parkinson’s disease is the second most common neurodegenerative disease after Alzheimer’s disease.

It is mostly characterized by the presence of motor difficulties. However, it can also be accompanied by cognitive disorders which have an equally significant impact on the quality of life of patients and which are not relieved by any treatment.

Among the functions affected by Parkinson’s diseas…

NCT05931575 — Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson’s Disease

The aim of this phase Ila trial is to provide evidence on safety, tolerability and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with early Parkinson’s disease (PD). Fasudil has shown neuroprotective and pro-regenerative effects, modulated microglial activity and attenuated alpha-synuclein aggregation in PD models in vitro and in vivo. It has been licensed in Japan since 1995 f…

NCT06697626 — Validation of a Novel Functional Food Designed to Meet the Nutritional Needs of People Living With Parkinson’s Disease

Constipation is a common complication and non-motor symptom of Parkinson’s disease (PD) and affects up to 80% of people with PD. It is in fact within the non-motor symptoms that nutrition and dietetic intervention could have the greatest impact. Research suggests that increasing the amount of fibre in the diet could help to alleviate the effects of constipation. Inulin is a type of fibre widely…

NCT07678983 — WHOLE-BODY VIBRATION IN PARKINSON DISEASE

The aim of this study is to evaluate the effects of different frequencies of Whole Body Vibration (WBV) application on balance, gait, cognitive functions, and dual-task performance in patients with Parkinson’s disease.

Study Hypotheses:

H0.1 - There is no effect of different frequencies of WBV application on balance performance in patients with Parkinson’s disease.

H1.1 - There is an effect …

Not Yet Recruiting

NCT07679529 — The Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Depression in PD

This study is a double blind comparative study examining the effectiveness of the transcutaneous auricular vagus nerve stimulation treatment on Parkinson’s disease patients with depression. The investigators hypothesize that taVNS will improve depression and cortical activity in Parkinson’s disease patients with depression.

NCT07685444 — A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Injection of LY-N001 Injection for the Treatment of Moderate to Advanced Parkinson’s Disease With GBA1 Mutations

This is a prospective, single-arm, single-dose clinical study designed to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of LY-N001 Injection in patients with moderate-to-advanced Parkinson’s disease carrying GBA1 mutations. The study consists of a main study phase and a long-term follow-up phase.

NCT07673146 — Probing Gut-Brain Communication in Parkinson’s Disease

Administering transcutaneous vagus nerve stimulation in patients with Parkinson’s disease to see how it affects stomach and brain activity.

NCT07681219 — LRRK2 Parkinson’s Disease Fingerprint

The goal of this interventional monocentric study is to identify molecular and clinical markers of LRRK2-related Parkinson’s disease through blood markers analysis and deep clinical phenotyping. Patients who meet the inclusion criteria, after signing the informed consent form will be clinically evaluated by a neurologist expert in movement disorders. Eventually, patients will undergo a blood sa…

NCT07675408 — Validation of cueStim for Reduction of Freezing of Gait in Parkinson’s Disease

The goal of this clinical trial is to learn if the cueStim device can reduce the duration of freezing of gait (FoG) that occurs in patients with Parkinson’s Disease. The study will compare two modes of operation of the cueStim device; both modes of operation use the same wearable device. The purpose of the study is to compare how the two modes affect symptoms across study participants. Because …

NCT07647614 — A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson’s Disease

The goal of this clinical trial is to learn if this study drug, ENERGI-F705 Tablets, is safe and works to treat participants who have Parkinson’s disease and are currently on standard-of-care antiparkinsonian medications. The main question it aims to answer is:

Does ENERGI-F705 Tablets work to treat Parkinson’s disease when used with standard-of-care treatment?

Investigators will compare the …

Enrolling by Invitation

NCT07525973 — The Effect of Eye Exercises in Parkinson’s Disease

Parkinson’s disease is commonly associated with impaired gait, postural instability, reduced physical function, and increased concern about falling, all of which contribute substantially to disability and reduced quality of life. Exercise-based rehabilitation is increasingly recommended as a core non-pharmacological strategy for improving mobility and balance in people with Parkinson’s disease….

Completed Trials

NCT01019343 — Physiological Investigations of Movement Disorders

Background:

• Previous studies have given researchers information on how the brain controls movement, how people learn to make fine, skilled movements, and why some people have movement disorders. However, further research is needed to learn more about the causes of most movement disorders, such as Parkinson’s disease.
• By using small, specialized studies to evaluate people with movement diso…

NCT01496599 — Imaging Biomarkers in Parkinson s Disease

Background:

- Parkinson s disease (PD) causes slow movement, stiffness, and tremor. It results from the loss of a brain chemical called dopamine. PD gets worse over time, but researchers do not fully understand why the brain cells that produce dopamine stop working or die in people with PD. This study will use different ways of imaging the brain and brain chemicals to look at PD. It will comp…

NCT01621581 — AAV2-GDNF for Advanced Parkinson s Disease

Background:

- Glial cell line-derived neurotrophic factor (GDNF) is a chemical that may help protect and strengthen brain cells that produce dopamine. Dopamine is a chemical that affects brain function. People with Parkinson’s disease (PD) have problems producing dopamine in the brain. Researchers want to see if gene transfer can help deliver GDNF into the area of the brain that is damaged by…

NCT05036473 — A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson’s Disease

It is a phase II randomized, parallel, double-blind, placebo-controlled, multi-center clinical trial of the efficacy and safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in patients with Parkinson’s disease. The objective of the study is to access the safety and efficacy of WD-1603 carbidopa-levodopa extended-release tablets in patients with Parkinson’s disease.

NCT05298150 — Remote Dynamic Cycling for the Customized Off-site Rehab in Parkinson’s Disease

This research will develop novel and accessible way to deliver effective and customized rehab to those suffering from common and devastating neurodegenerative condition called Parkinson’s disease. The investigators will examine the efficacy of novel rehab technique that can be monitored and modified in real-time but over virtual interface using a remotely located device in a paradigm called dyn…

NCT05510739 — Support for Physical Activity in Everyday Life With Parkinson’s Disease

This study aims to determine the effects of a motor-cognitive exercise intervention, delivered in the home environment using eHealth methods, among people with Parkinson’s disease. The intervention will support and motivate motor training, combined with cognitive training, aimed at attentional and executive functions, among people at mild-moderate disease stages. The main hypothesis is that uns…

NCT07687732 — Vibrotactile Stimulation for Parkinson’s Disease

Investigation on whether and how vibrotactile stimulation applied on the fingertips affects beta power in the subthalamic nucleus.

NCT06329141 — A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson’s Disease Patients

1. Study Objective

   - To assess the efficacy and safety of vutiglabridin in early Parkindson’s disease patients

2. Background Glaceum Inc. has evaluated the safety, tolerability, and pharmacokinetic/pharmacodynamic properties of vutiglabridin in healthy subjects through its Phase 1 trials, and is planning to perform this Phase 2a trial to assess the efficacy and safety of vutiglabridin in e…

NCT07264114 — Aquatic High-Intensity Interval Training for Parkinson’s Disease

This randomized, single-center, parallel-group superiority trial will evaluate the effect of an 8-week aquatic High-Intensity Interval Training (HIIT) program on balance, physical function, and sarcopenia-related outcomes in individuals with Parkinson’s disease (PD). The intervention aims to deliver Tabata-style aquatic HIIT (3 sessions/week) in a therapeutic pool to determine adherence and pre…